[go: up one dir, main page]

CU24365B1 - Derivados de oxazolidin-2-ona-pirimidina - Google Patents

Derivados de oxazolidin-2-ona-pirimidina

Info

Publication number
CU24365B1
CU24365B1 CU2015000050A CU20150050A CU24365B1 CU 24365 B1 CU24365 B1 CU 24365B1 CU 2015000050 A CU2015000050 A CU 2015000050A CU 20150050 A CU20150050 A CU 20150050A CU 24365 B1 CU24365 B1 CU 24365B1
Authority
CU
Cuba
Prior art keywords
pyrimidine
oxazolidin
ona
derivatives
pi3k
Prior art date
Application number
CU2015000050A
Other languages
English (en)
Other versions
CU20150050A7 (es
Inventor
Robin Alec Fairhurst
Pascal Furet
Frank Stephan Kalthoff
Andreas Lerchner
Heinrich Rueeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150050A7 publication Critical patent/CU20150050A7/es
Publication of CU24365B1 publication Critical patent/CU24365B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con compuestos de oxazolidin -2-ona pirimidina sustituidos de fórmula I, que actúan como inhibidores de la PI3K (fosfatidilinositol-3-quinasa), en donde dichos compuestos son útiles para el tratamiento de condiciones, enfermedades y trastornos dependientes de PI3K tales como cánceres de piel no melanoma, etapas pre malignas de cánceres de piel no melanoma u otros trastornos hiperproliferativos causados por la desregulación de los fibroblastos de la piel.</p>
CU2015000050A 2012-11-12 2013-11-11 Derivados de oxazolidin-2-ona-pirimidina CU24365B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
PCT/IB2013/060052 WO2014072956A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives

Publications (2)

Publication Number Publication Date
CU20150050A7 CU20150050A7 (es) 2015-11-27
CU24365B1 true CU24365B1 (es) 2018-10-04

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2015000050A CU24365B1 (es) 2012-11-12 2013-11-11 Derivados de oxazolidin-2-ona-pirimidina

Country Status (42)

Country Link
US (3) US9296733B2 (es)
EP (2) EP3199158B1 (es)
JP (1) JP6262245B2 (es)
KR (1) KR102153763B1 (es)
CN (1) CN104718204B (es)
AP (1) AP2015008347A0 (es)
AR (1) AR093408A1 (es)
AU (1) AU2013343022B2 (es)
BR (1) BR112015010136A2 (es)
CA (1) CA2890942C (es)
CL (1) CL2015001202A1 (es)
CO (1) CO7380758A2 (es)
CR (1) CR20150248A (es)
CU (1) CU24365B1 (es)
CY (1) CY1119391T1 (es)
DK (1) DK2922848T5 (es)
EA (2) EA029714B1 (es)
EC (1) ECSP15025093A (es)
ES (1) ES2641820T3 (es)
HR (1) HRP20171425T1 (es)
HU (1) HUE034492T2 (es)
IL (1) IL238239A (es)
IN (1) IN2015DN02912A (es)
JO (1) JO3334B1 (es)
LT (1) LT2922848T (es)
MA (1) MA38076A1 (es)
MX (1) MX363436B (es)
MY (1) MY174239A (es)
NZ (1) NZ706591A (es)
PE (1) PE20151006A1 (es)
PH (1) PH12015501053A1 (es)
PL (1) PL2922848T3 (es)
PT (1) PT2922848T (es)
RS (1) RS56336B1 (es)
SG (1) SG11201503447QA (es)
SI (1) SI2922848T1 (es)
TN (1) TN2015000120A1 (es)
TW (1) TWI608005B (es)
UA (1) UA114001C2 (es)
UY (1) UY35128A (es)
WO (1) WO2014072956A1 (es)
ZA (1) ZA201502175B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN108348508A (zh) 2015-09-24 2018-07-31 德雷克塞尔大学 治疗或预防皮肤障碍的新型组合物和方法
JP7118509B2 (ja) 2016-05-18 2022-08-16 トルク アーゲー 皮膚病変の治療
AU2017265384B2 (en) * 2016-05-18 2023-02-23 The Trustees Of The University Of Pennsylvania Treatment of skin lesions
TW201929861A (zh) 2017-11-06 2019-08-01 瑞士商諾華公司 包含㗁唑啶-2-酮-嘧啶衍生物之調配物
SG11202004589SA (en) 2017-11-23 2020-06-29 Piqur Therapeutics Ag Treatment of skin disorders
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921148B1 (es) 1970-12-28 1974-05-30
JPS4921149B1 (es) 1970-12-28 1974-05-30
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5358945A (en) 1990-07-03 1994-10-25 Mitsui Petrochemical Industries, Ltd. Pyrimidine compound and pharmaceutically acceptable salts thereof
US5786355A (en) 1995-04-13 1998-07-28 Taiho Pharmaceutical Co., Ltd. 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
KR100563514B1 (ko) 1997-07-24 2006-03-27 젠야쿠코교가부시키가이샤 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
WO2000043373A2 (en) 1999-01-22 2000-07-27 Amgen Inc. Kinase inhibitors
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Links to SRC kinase inhibition
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE60005355T2 (de) 1999-07-15 2004-07-01 Pharmacopeia, Inc. Bradikinin b1 rezeptor antagonisten
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
WO2002022607A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
CA2448626A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1485376B1 (en) 2002-03-15 2007-06-27 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7405221B2 (en) 2002-09-27 2008-07-29 Merck & Co., Inc. Substituted pyrimidines
WO2004032716A2 (en) 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
EP2316831B1 (en) 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1610774A4 (en) 2003-04-09 2008-07-16 Exelixis Inc TIE-2 MODULATORS AND METHODS OF USE
JP2007523875A (ja) 2003-07-15 2007-08-23 ニューロジェン・コーポレーション バニロイド受容体リガンドとしての置換ピリミジン−４−イルアミン類縁体
EP1644358A2 (en) 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2005099711A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
EP1827434B1 (en) * 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US20080132509A1 (en) 2004-12-13 2008-06-05 Neurogen Corporation Substituted Biaryl Analogues
AU2005317176A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
CN103274961B (zh) 2004-12-28 2016-05-18 阿西纳斯公司 治疗细胞增殖紊乱的化合物和方法
WO2006078992A2 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
WO2006090167A2 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
US20070078135A1 (en) 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
EP1979325A1 (en) 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2012794B1 (en) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
TW200833342A (en) 2006-12-28 2008-08-16 Basf Ag 2-substituted pyrimidines I in therapy
KR20090108124A (ko) 2007-02-06 2009-10-14 노파르티스 아게 Ｐｉ 3-키나제 억제제 및 그의 사용 방법
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
KR20100031639A (ko) 2007-07-09 2010-03-23 아스트라제네카 아베 증식성 질환의 치료용 삼중 치환된 피리미딘 유도체
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
BRPI0908049A2 (pt) 2008-03-05 2015-08-11 Novartis Ag Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
WO2009118324A1 (en) 2008-03-26 2009-10-01 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2349275B1 (en) 2008-10-31 2017-03-08 Novartis AG Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
AU2010211672B2 (en) 2009-02-06 2016-08-04 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US8759356B2 (en) 2009-05-19 2014-06-24 Dow Agrosciences, Llc. Compounds and methods for controlling fungi
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
US20110230476A1 (en) 2009-09-09 2011-09-22 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
CN103140479B (zh) 2010-10-01 2015-04-08 诺华有限公司 制造嘧啶衍生物的方法
SMT201700533T1 (it) 2010-10-18 2018-01-11 Cerenis Therapeutics Holding Sa Composti, composizioni e metodi utili per la mobilitazione del colesterolo
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012109423A1 (en) 2011-02-11 2012-08-16 Dana-Farber Cancer Institute, Inc. Method of inhibiting hamartoma tumor cells
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
BR112014004577A2 (pt) 2011-09-01 2017-04-04 Novartis Ag inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2013052395A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
EP2849756A1 (en) * 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
EP2858631A1 (en) 2012-06-06 2015-04-15 Novartis AG Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
US20150216870A1 (en) 2012-08-16 2015-08-06 Novartis Ag Combination of PI3K Inhibitor and C-Met Inhibitor
IN2015DN01331A (es) 2012-10-23 2015-07-03 Novartis Ag
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903176A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
AP2015008347A0 (en) 2015-04-30
US9296733B2 (en) 2016-03-29
PT2922848T (pt) 2017-10-05
ECSP15025093A (es) 2019-03-29
HK1209108A1 (en) 2016-03-24
AU2013343022A1 (en) 2015-04-23
US20140135330A1 (en) 2014-05-15
WO2014072956A1 (en) 2014-05-15
TN2015000120A1 (en) 2016-06-29
US20160168145A1 (en) 2016-06-16
AR093408A1 (es) 2015-06-03
IL238239A (en) 2017-05-29
HUE034492T2 (en) 2018-02-28
MA38076A1 (fr) 2018-02-28
PH12015501053B1 (en) 2015-07-27
UA114001C2 (xx) 2017-04-10
EP3199158B1 (en) 2019-04-17
BR112015010136A2 (pt) 2017-07-11
EA201790289A1 (ru) 2017-06-30
CL2015001202A1 (es) 2015-07-03
SI2922848T1 (sl) 2017-10-30
DK2922848T5 (en) 2017-10-30
CU20150050A7 (es) 2015-11-27
CO7380758A2 (es) 2015-09-10
MX2015005914A (es) 2015-09-08
EA027987B1 (ru) 2017-09-29
LT2922848T (lt) 2017-09-25
US20190382399A1 (en) 2019-12-19
US10202371B2 (en) 2019-02-12
SG11201503447QA (en) 2015-05-28
JP2015536974A (ja) 2015-12-24
CY1119391T1 (el) 2018-02-14
MX363436B (es) 2019-03-22
AU2013343022B2 (en) 2015-08-20
EP3199158A1 (en) 2017-08-02
PL2922848T3 (pl) 2017-12-29
CN104718204A (zh) 2015-06-17
CA2890942C (en) 2021-01-12
CA2890942A1 (en) 2014-05-15
TWI608005B (zh) 2017-12-11
HRP20171425T1 (hr) 2017-11-17
DK2922848T3 (da) 2017-10-09
JP6262245B2 (ja) 2018-01-17
CN104718204B (zh) 2017-11-28
RS56336B1 (sr) 2017-12-29
JO3334B1 (ar) 2019-03-13
ZA201502175B (en) 2018-05-30
EA201590929A1 (ru) 2015-08-31
PH12015501053A1 (en) 2015-07-27
EP2922848A1 (en) 2015-09-30
PE20151006A1 (es) 2015-07-04
MY174239A (en) 2020-04-01
EA029714B1 (ru) 2018-05-31
TW201427974A (zh) 2014-07-16
EP2922848B1 (en) 2017-06-28
CR20150248A (es) 2015-07-01
KR102153763B1 (ko) 2020-09-09
UY35128A (es) 2014-06-30
ES2641820T3 (es) 2017-11-14
NZ706591A (en) 2016-03-31
IN2015DN02912A (es) 2015-09-11
KR20150082295A (ko) 2015-07-15

Similar Documents

Publication Publication Date Title
CU24365B1 (es) Derivados de oxazolidin-2-ona-pirimidina
DOP2014000194A (es) COMPUESTOS DE OXAZOLIDIN- 2- ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
TR201904340T4 (tr) Yeni bileşikler.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
IN2015DN00372A (es)
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
UA111198C2 (uk) Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX387590B (es) Compuestos policíclicos como inhibidores de tirosina quinasa de bruton.
ECSP12012198A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks
CR20140374A (es) Nuevos usos pediatricos del cabazitaxel
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
CU20110012A7 (es) Derivados de heteroarilo como inhibidores de dgat1
GB201016442D0 (en) Novel acridine derivatives